The Best of Canadian Science and Technology
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
Mackie Research analyst André Uddin says investors can expect long-term organic growth and margin improvements from specialty pharma company Medexus … [Read more...] about Medexus Pharma is “significantly undervalued”: Mackie Research
Raymond James analyst Rahul Sarugaser delivered an update to clients on Cardiol Therapeutics (Cardiol Therapeutics Stock Quote, Chart, News TSX:CRDL) … [Read more...] about Raymond James trims price target on Cardiol Therapeutics
A delay in commercialization is cause for a lowering of the price target for Cardiol Therapeutics (Cardiol Therapeutics Stock Quote, Chart, News … [Read more...] about Cardiol Therapeutics has price target trimmed at AltaCorp Capital
A potential catalyst is coming up for HLS Therapeutics (HLS Therapeutics Stock Quote, Chart, News TSX:HLS), according to Stifel GMP analyst Justin … [Read more...] about There’s too much negativity built into HLS Therapeutics share price: Stifel
Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has had a turbulent couple of days of trading, but Echelon Wealth Partners … [Read more...] about Antibe Therapeutics is undervalued, Echelon analyst Loe says
Shares of Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News TSX:MDNA) have skyrocketed over the past few months, but there’s … [Read more...] about Medicenna has lots left in the tank, says Bloom Burton
Mackie Research Capital analyst André Uddin ussued an update to clients Monday on Medexus Pharmaceuticals (Medexus Pharmaceuticals Stock Quote, Chart, … [Read more...] about Medexus Pharmaceuticals has price target trimmed at Mackie Research
In an update to clients last Friday, Stifel GMP analyst Justin Keywood said cardiovascular and central nervous system drug developer HLS Therapeutics … [Read more...] about HLS Therapeutics is undervalued, Stifel says
Stifel GMP analyst Justin Keywood released on Monday a flash update to clients, saying a new Health Canada decision has reinforced the status of HLS … [Read more...] about HLS Therapeutics is still a buy, Stifel Canada says
Investment bankers Paradigm Capital launched coverage on Wednesday of drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News … [Read more...] about Will Antibe Therapeutics break out in 2020?
